Korea’s health insurance outlays hit US$30bn
August 31 2017 by InsuranceAsia News-
Claims complexity, fraud and lack of quality data key challenges for regional health insurers
- October 30
Reinsurers' deep actuarial expertise and access to large data sets can help P&C carriers refine risk assessment and pricing strategies, says Peak Re’s Jasmine Miow.
-
Scor promotes Paula Bourke to CEO of life and health for ANZ
- October 16
Sydney-based Bourke was most recently the reinsurer's regional deputy CEO and global head of proposition and innovation, L&H.
-
Gallagher Re strengthens life and health reinsurance team with two senior hires
- October 15
The reinsurer has appointed Sanjeeb Kumar as chairman of L&H reinsurance for India, and Addise Li as head of L&H reinsurance in China and Hong Kong.
-
Exclusive: Peak Re eyes South-East Asia A&H growth with senior RGA hire
- October 15
The Hong Kong-based reinsurer has appointed Ashish Kanakia as vice president, underwriting, A&H, South-East Asia markets.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | The hunt for diversification and performance revitalizes appetite for Asian currency bonds
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.